PHARMING GROUP NV (PHARM.AS)

NL0010391025 - Common Stock

0.881  +0.01 (+1.5%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029
Revenue
YoY % growth
198.871M
-6.27%		205.622M
3.39%		245.316M
19.30%		294.3M
19.97%
EBITDA
YoY % growth
43.61M
-48.43%		23.555M
-45.99%		10.538M
-55.26%		8.056M
-23.55%		N/AN/A
EBIT
YoY % growth
24M
-68.53%		10.367M
-56.80%		-5.387M
-151.96%		3.65M
167.76%
Operating Margin
12.07%5.04%-2.20%1.24%
EPS
YoY % growth
0.02
-55.95%		N/A-0.020.01
153.11%		N/AN/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth		0.01
142.41%
Revenue
Q2Q % growth		70.478M
65.67%
EBITDA
Q2Q % growth		6.695M
EBIT
Q2Q % growth		2.112M
115.46%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 0.00
80.00%		0.01-0.01-138.83%
Q3 2023
Q2Q % growth		 0.01
-61.54%		-0.030.03118.67%
Q2 2023
Q2Q % growth		 0.00
-100.00%		-0.010.01100.00%
Q1 2023
Q2Q % growth		 -0.02
-440.00%		-0.01-0.01-153.92%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2023
Q2Q % growth		 245.316M
349.12%		74.933M170.383M227.38%
Q3 2023
Q2Q % growth		 66.661M
22.90%		63.18M3.481M5.51%
Q2 2023
Q2Q % growth		 54.897M
9.47%		54.363M534K0.98%
Q1 2023
Q2Q % growth		 42.541M
-8.74%		49.595M-7.054M-14.22%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPSN/A N/A -34% 90.53%
RevenueN/A N/A 1.13% 8.14%